The private label CBD gummies market is forecast to reach USD 1,382.2 million by 2036, expanding at a compound annual growth rate of 7.9% from 2026, according to a report by Future Market Insights (FMI). Valued at USD 598.9 million in 2025 and projected at USD 646.2 million in 2026, the market is being fueled by wellness brands increasingly opting for outsourced manufacturing to enter the CBD edibles segment without heavy capital investment in extraction or confectionery infrastructure.
White label gummies are expected to dominate the service model, capturing 46.2% of global demand in 2026, as they offer shorter commercialization timelines and lower formulation costs. Broad-spectrum CBD gummies lead the spectrum segment with a 42.8% share, driven by consumer preference for THC-free products that retain multiple cannabinoids. Brand websites account for 39.6% of sales channels, enabling direct-to-consumer education and subscription models.
The United States is the fastest-growing market, with an 8.5% CAGR through 2036, supported by a mature CBD ecosystem and strong direct-to-consumer infrastructure. Key players include CBD Nationwide, Extract Labs, cbdMD, Inc., Charlotte's Web Holdings, Inc., CV Sciences, Inc., Medterra CBD LLC, British Cannabis, Cannaray Limited, MediPharm Labs Corp., and Little Green Pharma Ltd.
According to Nandini Roy Choudhury, Principal Consultant for Food & Beverage at FMI, private label CBD gummies provide a faster route into the expanding CBD edibles market, with competitive advantage depending on suppliers that combine formulation expertise with comprehensive testing and compliant labeling.
For detailed market forecasts and competitive benchmarking, visit FMI's sample report. The full report is accessible at FMI's brochure page.
